In vitro and in vivo Synergistic Effects of Florfenicol and Thiamphenicol in Combination Against Swine Actinobacillus pleuropneumoniae and Pasteurella multocida
Potential synergism between florfenicol (FF) and thiamphenicol (TAP) was investigated for in vitro efficacy against Actinobacillus pleuropneumoniae and/or Pasteurella multocida as well as in vivo efficacy in swine. Among isolates of A. pleuropneumoniae (n = 58) and P. multocida (n = 79) from pigs in...
Saved in:
| Published in | Frontiers in microbiology Vol. 10; p. 2430 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Frontiers Media S.A
30.10.2019
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Potential synergism between florfenicol (FF) and thiamphenicol (TAP) was investigated for in vitro efficacy against Actinobacillus pleuropneumoniae and/or Pasteurella multocida as well as in vivo efficacy in swine. Among isolates of A. pleuropneumoniae (n = 58) and P. multocida (n = 79) from pigs in Taiwan that were tested, high percentages showed resistance to FF (52 and 53%, respectively) and TAP (57 and 53%, respectively). Checkerboard microdilution assay indicated that synergism [fractional inhibitory concentration index (FICI) ≤ 0.5] was detected in 17% of A. pleuropneumoniae (all serovar 1) and 24% of P. multocida isolates. After reconfirming the strains showing FICI ≤ 0.625 with time kill assay, the synergism increased to around 32% against both bacteria and the number could further increase to 40% against resistant A. pleuropneumoniae and 65% against susceptible P. multocida isolates. A challenge-treatment trial in pigs with P. multocida showed that the FF + TAP dosage at ratios correspondent to their MIC deduction was equally effective to the recommended dosages. Further on the combination, the resistant mutation frequency is very low when A. pleuropneumoniae is grown with FF + TAP and similar to the exposure to sub-inhibitory concentration of FF or TAP alone. The degree of minimum inhibitory concentration (MIC) reduction in FF could reach 75% (1/4 MIC) or more (up to 1/8 MIC for P. multocida, 1/16 for A. pleuropneumoniae) when combined with 1/4 MIC of TAP (or 1/8 for A. pleuropneumoniae). The synergism or FICI ≤ 0.625 of FF with oxytetracycline (47%), doxycycline (69%), and erythromycin (56%) was also evident, and worth further investigation for FF as a central modulator facilitating synergistic effects with these antimicrobials. Taken together, synergistic FF + TAP combination was effective against swine pulmonary isolates of A. pleuropneumoniae and P. multocida both in vitro and in vivo. Thus, this study may offer a potential alternative for the treatment of A. pleuropneumoniae and P. multocida infections and has the potential to greatly reduce drug residues and withdrawal time.Potential synergism between florfenicol (FF) and thiamphenicol (TAP) was investigated for in vitro efficacy against Actinobacillus pleuropneumoniae and/or Pasteurella multocida as well as in vivo efficacy in swine. Among isolates of A. pleuropneumoniae (n = 58) and P. multocida (n = 79) from pigs in Taiwan that were tested, high percentages showed resistance to FF (52 and 53%, respectively) and TAP (57 and 53%, respectively). Checkerboard microdilution assay indicated that synergism [fractional inhibitory concentration index (FICI) ≤ 0.5] was detected in 17% of A. pleuropneumoniae (all serovar 1) and 24% of P. multocida isolates. After reconfirming the strains showing FICI ≤ 0.625 with time kill assay, the synergism increased to around 32% against both bacteria and the number could further increase to 40% against resistant A. pleuropneumoniae and 65% against susceptible P. multocida isolates. A challenge-treatment trial in pigs with P. multocida showed that the FF + TAP dosage at ratios correspondent to their MIC deduction was equally effective to the recommended dosages. Further on the combination, the resistant mutation frequency is very low when A. pleuropneumoniae is grown with FF + TAP and similar to the exposure to sub-inhibitory concentration of FF or TAP alone. The degree of minimum inhibitory concentration (MIC) reduction in FF could reach 75% (1/4 MIC) or more (up to 1/8 MIC for P. multocida, 1/16 for A. pleuropneumoniae) when combined with 1/4 MIC of TAP (or 1/8 for A. pleuropneumoniae). The synergism or FICI ≤ 0.625 of FF with oxytetracycline (47%), doxycycline (69%), and erythromycin (56%) was also evident, and worth further investigation for FF as a central modulator facilitating synergistic effects with these antimicrobials. Taken together, synergistic FF + TAP combination was effective against swine pulmonary isolates of A. pleuropneumoniae and P. multocida both in vitro and in vivo. Thus, this study may offer a potential alternative for the treatment of A. pleuropneumoniae and P. multocida infections and has the potential to greatly reduce drug residues and withdrawal time. |
|---|---|
| AbstractList | Potential synergism between florfenicol (FF) and thiamphenicol (TAP) was investigated for
in vitro
efficacy against
Actinobacillus pleuropneumoniae
and/or
Pasteurella multocida
as well as
in vivo
efficacy in swine. Among isolates of
A. pleuropneumoniae
(
n
= 58) and
P. multocida
(
n
= 79) from pigs in Taiwan that were tested, high percentages showed resistance to FF (52 and 53%, respectively) and TAP (57 and 53%, respectively). Checkerboard microdilution assay indicated that synergism [fractional inhibitory concentration index (FICI) ≤ 0.5] was detected in 17% of
A. pleuropneumoniae
(all serovar 1) and 24% of
P. multocida
isolates. After reconfirming the strains showing FICI ≤ 0.625 with time kill assay, the synergism increased to around 32% against both bacteria and the number could further increase to 40% against resistant
A. pleuropneumoniae
and 65% against susceptible
P. multocida
isolates. A challenge-treatment trial in pigs with
P. multocida
showed that the FF + TAP dosage at ratios correspondent to their MIC deduction was equally effective to the recommended dosages. Further on the combination, the resistant mutation frequency is very low when
A. pleuropneumoniae
is grown with FF + TAP and similar to the exposure to sub-inhibitory concentration of FF or TAP alone. The degree of minimum inhibitory concentration (MIC) reduction in FF could reach 75% (1/4 MIC) or more (up to 1/8 MIC for
P. multocida
, 1/16 for
A. pleuropneumoniae
) when combined with 1/4 MIC of TAP (or 1/8 for
A. pleuropneumoniae
). The synergism or FICI ≤ 0.625 of FF with oxytetracycline (47%), doxycycline (69%), and erythromycin (56%) was also evident, and worth further investigation for FF as a central modulator facilitating synergistic effects with these antimicrobials. Taken together, synergistic FF + TAP combination was effective against swine pulmonary isolates of
A. pleuropneumoniae
and
P. multocida
both
in vitro
and
in vivo.
Thus, this study may offer a potential alternative for the treatment of
A. pleuropneumoniae
and
P. multocida
infections and has the potential to greatly reduce drug residues and withdrawal time. Potential synergism between florfenicol (FF) and thiamphenicol (TAP) was investigated for in vitro efficacy against Actinobacillus pleuropneumoniae and/or Pasteurella multocida as well as in vivo efficacy in swine. Among isolates of A. pleuropneumoniae (n = 58) and P. multocida (n = 79) from pigs in Taiwan that were tested, high percentages showed resistance to FF (52 and 53%, respectively) and TAP (57 and 53%, respectively). Checkerboard microdilution assay indicated that synergism [fractional inhibitory concentration index (FICI) ≤ 0.5] was detected in 17% of A. pleuropneumoniae (all serovar 1) and 24% of P. multocida isolates. After reconfirming the strains showing FICI ≤ 0.625 with time kill assay, the synergism increased to around 32% against both bacteria and the number could further increase to 40% against resistant A. pleuropneumoniae and 65% against susceptible P. multocida isolates. A challenge-treatment trial in pigs with P. multocida showed that the FF + TAP dosage at ratios correspondent to their MIC deduction was equally effective to the recommended dosages. Further on the combination, the resistant mutation frequency is very low when A. pleuropneumoniae is grown with FF + TAP and similar to the exposure to sub-inhibitory concentration of FF or TAP alone. The degree of minimum inhibitory concentration (MIC) reduction in FF could reach 75% (1/4 MIC) or more (up to 1/8 MIC for P. multocida, 1/16 for A. pleuropneumoniae) when combined with 1/4 MIC of TAP (or 1/8 for A. pleuropneumoniae). The synergism or FICI ≤ 0.625 of FF with oxytetracycline (47%), doxycycline (69%), and erythromycin (56%) was also evident, and worth further investigation for FF as a central modulator facilitating synergistic effects with these antimicrobials. Taken together, synergistic FF + TAP combination was effective against swine pulmonary isolates of A. pleuropneumoniae and P. multocida both in vitro and in vivo. Thus, this study may offer a potential alternative for the treatment of A. pleuropneumoniae and P. multocida infections and has the potential to greatly reduce drug residues and withdrawal time. Potential synergism between florfenicol (FF) and thiamphenicol (TAP) was investigated for in vitro efficacy against Actinobacillus pleuropneumoniae and/or Pasteurella multocida as well as in vivo efficacy in swine. Among isolates of A. pleuropneumoniae (n = 58) and P. multocida (n = 79) from pigs in Taiwan that were tested, high percentages showed resistance to FF (52 and 53%, respectively) and TAP (57 and 53%, respectively). Checkerboard microdilution assay indicated that synergism [fractional inhibitory concentration index (FICI) ≤ 0.5] was detected in 17% of A. pleuropneumoniae (all serovar 1) and 24% of P. multocida isolates. After reconfirming the strains showing FICI ≤ 0.625 with time kill assay, the synergism increased to around 32% against both bacteria and the number could further increase to 40% against resistant A. pleuropneumoniae and 65% against susceptible P. multocida isolates. A challenge-treatment trial in pigs with P. multocida showed that the FF + TAP dosage at ratios correspondent to their MIC deduction was equally effective to the recommended dosages. Further on the combination, the resistant mutation frequency is very low when A. pleuropneumoniae is grown with FF + TAP and similar to the exposure to sub-inhibitory concentration of FF or TAP alone. The degree of minimum inhibitory concentration (MIC) reduction in FF could reach 75% (1/4 MIC) or more (up to 1/8 MIC for P. multocida, 1/16 for A. pleuropneumoniae) when combined with 1/4 MIC of TAP (or 1/8 for A. pleuropneumoniae). The synergism or FICI ≤ 0.625 of FF with oxytetracycline (47%), doxycycline (69%), and erythromycin (56%) was also evident, and worth further investigation for FF as a central modulator facilitating synergistic effects with these antimicrobials. Taken together, synergistic FF + TAP combination was effective against swine pulmonary isolates of A. pleuropneumoniae and P. multocida both in vitro and in vivo. Thus, this study may offer a potential alternative for the treatment of A. pleuropneumoniae and P. multocida infections and has the potential to greatly reduce drug residues and withdrawal time.Potential synergism between florfenicol (FF) and thiamphenicol (TAP) was investigated for in vitro efficacy against Actinobacillus pleuropneumoniae and/or Pasteurella multocida as well as in vivo efficacy in swine. Among isolates of A. pleuropneumoniae (n = 58) and P. multocida (n = 79) from pigs in Taiwan that were tested, high percentages showed resistance to FF (52 and 53%, respectively) and TAP (57 and 53%, respectively). Checkerboard microdilution assay indicated that synergism [fractional inhibitory concentration index (FICI) ≤ 0.5] was detected in 17% of A. pleuropneumoniae (all serovar 1) and 24% of P. multocida isolates. After reconfirming the strains showing FICI ≤ 0.625 with time kill assay, the synergism increased to around 32% against both bacteria and the number could further increase to 40% against resistant A. pleuropneumoniae and 65% against susceptible P. multocida isolates. A challenge-treatment trial in pigs with P. multocida showed that the FF + TAP dosage at ratios correspondent to their MIC deduction was equally effective to the recommended dosages. Further on the combination, the resistant mutation frequency is very low when A. pleuropneumoniae is grown with FF + TAP and similar to the exposure to sub-inhibitory concentration of FF or TAP alone. The degree of minimum inhibitory concentration (MIC) reduction in FF could reach 75% (1/4 MIC) or more (up to 1/8 MIC for P. multocida, 1/16 for A. pleuropneumoniae) when combined with 1/4 MIC of TAP (or 1/8 for A. pleuropneumoniae). The synergism or FICI ≤ 0.625 of FF with oxytetracycline (47%), doxycycline (69%), and erythromycin (56%) was also evident, and worth further investigation for FF as a central modulator facilitating synergistic effects with these antimicrobials. Taken together, synergistic FF + TAP combination was effective against swine pulmonary isolates of A. pleuropneumoniae and P. multocida both in vitro and in vivo. Thus, this study may offer a potential alternative for the treatment of A. pleuropneumoniae and P. multocida infections and has the potential to greatly reduce drug residues and withdrawal time. |
| Author | Kuo, Hung-Chih Chou, Chi-Chung Sung, Chi-Hsuan Yeh, Sze-Yu Rairat, Tirawat Lin, Tsai-Lu Vickroy, Thomas W. Rattanapanadda, Porjai |
| AuthorAffiliation | 3 Department of Physiological Sciences, College of Veterinary Medicine, University of Florida , Gainesville, FL , United States 1 Department of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University , Taichung , Taiwan 2 Department of Veterinary Medicine, College of Veterinary Medicine, National Chiayi University , Chiayi , Taiwan |
| AuthorAffiliation_xml | – name: 3 Department of Physiological Sciences, College of Veterinary Medicine, University of Florida , Gainesville, FL , United States – name: 1 Department of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University , Taichung , Taiwan – name: 2 Department of Veterinary Medicine, College of Veterinary Medicine, National Chiayi University , Chiayi , Taiwan |
| Author_xml | – sequence: 1 givenname: Porjai surname: Rattanapanadda fullname: Rattanapanadda, Porjai – sequence: 2 givenname: Hung-Chih surname: Kuo fullname: Kuo, Hung-Chih – sequence: 3 givenname: Thomas W. surname: Vickroy fullname: Vickroy, Thomas W. – sequence: 4 givenname: Chi-Hsuan surname: Sung fullname: Sung, Chi-Hsuan – sequence: 5 givenname: Tirawat surname: Rairat fullname: Rairat, Tirawat – sequence: 6 givenname: Tsai-Lu surname: Lin fullname: Lin, Tsai-Lu – sequence: 7 givenname: Sze-Yu surname: Yeh fullname: Yeh, Sze-Yu – sequence: 8 givenname: Chi-Chung surname: Chou fullname: Chou, Chi-Chung |
| BookMark | eNp1kstqGzEUhoeS0qRp9l1q2Y1d3WY02hSMSRpDoIWk0J3QaCRbQSNNJY1D3qaPGnnsQlOoFrocnf-TOOd_X5354HVVfURwSUjLP5vBqm6JIeJLiCmBb6oL1DR0QSD-efbX_ry6SukRlkEhLvO76pwgRjlj9UX1e-PB3uYYgPQ9sIfDPoD7Z6_j1qZsFbg2RqucQDDgxoVotLcquDn9YWflMO5OkSJeh6GzXmYbPFhtpfUpg_sn6zVYqWx96KSyzk0JjE5PMYxeT0PwVuoZ912mXMLaOQmGyeWgbC8_VG-NdElfndbL6sfN9cP6dnH37etmvbpbKEp4XlDWtwbXxHDcKQyJIXVNtWIMI92YlnbcdBhhjBWlWCIlucENM7yWRGGCenJZbY7cPshHMUY7yPgsgrRiDoS4FTKWejgt2hYqhHDNqIG0p1pCyTFpy3OtbFrKCuvLkTVO3aB7pX2O0r2Cvr7xdie2YS-KGnPOC-DTCRDDr0mnLAab1KEwXocpifLjhjFeOlpSm2OqiiGlqI1QNs8dKGTrBILi4BYxu0Uc3CJmtxQh_Ef453__lbwAJSnHvQ |
| CitedBy_id | crossref_primary_10_2903_j_efsa_2021_6859 crossref_primary_10_3389_fvets_2022_975673 crossref_primary_10_3390_ijms24108662 crossref_primary_10_1142_S1682648520500146 crossref_primary_10_3389_fvets_2021_751957 crossref_primary_10_3390_insects11070401 crossref_primary_10_1016_j_gce_2022_10_002 crossref_primary_10_3389_fvets_2022_811967 crossref_primary_10_1002_ange_202217623 crossref_primary_10_1016_j_psj_2025_104922 crossref_primary_10_1038_s41429_023_00659_2 crossref_primary_10_3389_fmicb_2022_998671 crossref_primary_10_3389_fvets_2021_759716 crossref_primary_10_1007_s11259_022_09917_4 crossref_primary_10_1002_anie_202217623 crossref_primary_10_3390_antibiotics9040185 |
| Cites_doi | 10.1046/j.1469-0691.2000.00149.x 10.1002/psc.2978 10.1177/030098589603300205 10.1038/nrmicro3270 10.1016/j.vetmic.2011.01.016 10.3389/fmicb.2016.00389 10.1128/AAC.00188-13 10.1292/jvms.70.99 10.29261/pakveti/2019.013 10.1371/journal.pone.0192387 10.1128/AAC.01245-15 10.1128/aac.39.9.1984 10.1186/s12917-018-1565-2 10.1038/s41598-017-09593-4 10.4103/0972-5229.132495 10.3382/japr.2011-00500 10.1093/infdis/154.4.670 10.1292/jvms.56.917 10.54846/jshap/1002 10.1128/AAC.00179-13 10.1136/vr.101863 10.1007/bf03192337 10.1136/vr.103554 10.1038/ja.2017.102 10.1016/0732-1 10.3390/molecules22030463 10.1016/j.aquaculture.2019.04.021 10.1128/aac.26.2.220 10.1016/s0034-5288(02)00037-1 10.1111/1751-7915.12432 10.3389/fmicb.2016.00470 10.1016/j.jmii.2013.05.007 10.1086/340246 10.1292/jvms.10-0243 10.1292/jvms.10-0339 10.1016/j.ijid.2017.07.019 10.1093/jac/dkg301 10.1128/AAC.05741-11 10.3389/fvets.2018.00184 10.1073/pnas.1806068115 10.1111/jvp.12385 10.1128/aac.40.8.1914 10.3389/fphar.2017.00553 10.1111/j.1574-695X.2008.00414.x 10.1292/jvms.70.1261 10.3389/fmicb.2017.00811 10.1128/aac.47.2.820-823.2003 10.1590/s0100-736x2015000800003 10.1023/A:1013397419995 10.1093/jac/dki204 10.1128/cmr.1.2.139 10.1016/j.ijid.2015.01.011 10.1016/j.vetmic.2014.03.014 10.1179/joc.2005.17.1.46 10.1111/j.1365-2885.2006.00727.x 10.1136/vr.104023 10.1016/j.vetmic.2014.04.008 10.1128/aac.47.8.2703-2705.2003 10.1371/journal.pone.0177568 |
| ContentType | Journal Article |
| Copyright | Copyright © 2019 Rattanapanadda, Kuo, Vickroy, Sung, Rairat, Lin, Yeh and Chou. Copyright © 2019 Rattanapanadda, Kuo, Vickroy, Sung, Rairat, Lin, Yeh and Chou. 2019 Rattanapanadda, Kuo, Vickroy, Sung, Rairat, Lin, Yeh and Chou |
| Copyright_xml | – notice: Copyright © 2019 Rattanapanadda, Kuo, Vickroy, Sung, Rairat, Lin, Yeh and Chou. – notice: Copyright © 2019 Rattanapanadda, Kuo, Vickroy, Sung, Rairat, Lin, Yeh and Chou. 2019 Rattanapanadda, Kuo, Vickroy, Sung, Rairat, Lin, Yeh and Chou |
| DBID | AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.3389/fmicb.2019.02430 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1664-302X |
| ExternalDocumentID | oai_doaj_org_article_880c112574f04d4ea0a92384ec8a6847 PMC6842999 10_3389_fmicb_2019_02430 |
| GrantInformation_xml | – fundername: Ministry of Science and Technology, Taiwan |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK ECGQY GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 PGMZT RNS RPM 7X8 5PM |
| ID | FETCH-LOGICAL-c439t-47d8f253f92bc203f3554ec7721e6f84b9fb21222c442a1ca9f267f95a3c231d3 |
| IEDL.DBID | M48 |
| ISSN | 1664-302X |
| IngestDate | Wed Aug 27 01:21:52 EDT 2025 Thu Aug 21 13:55:42 EDT 2025 Thu Jul 10 18:50:17 EDT 2025 Tue Jul 01 01:52:50 EDT 2025 Thu Apr 24 23:01:08 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c439t-47d8f253f92bc203f3554ec7721e6f84b9fb21222c442a1ca9f267f95a3c231d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Henrietta Venter, University of South Australia, Australia Reviewed by: Conny Turni, University of Queensland, Australia; Patrick Blackall, University of Queensland, Australia This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fmicb.2019.02430 |
| PMID | 31749775 |
| PQID | 2316779004 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_880c112574f04d4ea0a92384ec8a6847 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6842999 proquest_miscellaneous_2316779004 crossref_citationtrail_10_3389_fmicb_2019_02430 crossref_primary_10_3389_fmicb_2019_02430 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-10-30 |
| PublicationDateYYYYMMDD | 2019-10-30 |
| PublicationDate_xml | – month: 10 year: 2019 text: 2019-10-30 day: 30 |
| PublicationDecade | 2010 |
| PublicationTitle | Frontiers in microbiology |
| PublicationYear | 2019 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | McEwen (B44) 2002; 34 Pollini (B53) 2017; 23 Dayao (B15) 2014; 171 Liu (B40) 2015 Stipkovits (B60) 2001; 65 Wei (B71); 178 Hammer (B28) 2012; 56 Halbur (B27) 1996; 33 Lee (B37) 2017; 22 Choi (B13) 2011; 31 Moody (B45) 2004 Ahmed (B2) 2014; 18 Bayer (B6) 1984; 26 (B24) 1999 Rairat (B55) 2019; 39 Grzybowska (B26) 2004; 56 Mainardi (B43) 1995; 39 Priebe (B54) 2003; 47 Liu (B42) 2002; 27 Sweeney (B61) 2008; 9 (B48) 2015 Sweeney (B62) 2017; 25 Yang (B75) 2011; 73 Dorey (B18); 40 Abu-Basha (B1) 2012; 21 (B66) 2019 (B69) 2019 Pericas (B52) 2018; 13 Soren (B59) 2015; 59 Oliveira Filho (B50) 2015; 35 Leu (B38) 2014; 47 Chadwick (B11) 1986; 154 (B14) 2018 Lee (B36) 2010; 50 Yoo (B77) 2014; 174 Tascini (B63) 2013; 57 Andersson (B3) 2014; 12 Dong (B16) 2017; 8 Jong (B32) 2014; 172 Bartash (B5) 2017; 63 Oliveira Filho (B51) 2018; 14 Dowling (B19) 2002; 73 Tremblay (B67) 2017; 10 VanderWaal (B68) 2018; 115 Yoshimura (B78) 2002; 26 Ceccarelli (B10) 2013; 57 Drago (B20); 56 Kim (B34) 2008; 70 (B9) 2019 Morioka (B46) 2008; 70 Yeh (B76) 2017; 181 (B70) 2013 Boehme (B7) 2015 Assane (B4) 2019; 507 Kim (B33) 2011; 73 Jiang (B31) 2006; 29 Singh (B57) 2017; 70 Liao (B39) 2019 Eliopoulos (B22) 1988; 1 Inamoto (B30) 1994; 56 Ramírez-Castillo (B56) 2018; 5 (B65) 1999 Hsieh (B29) 1993; 16 (B64) 2015 Drago (B21); 17 White (B73) 1996; 40 Xie (B74) 2017; 8 (B23) 2000; 6 Smith (B58) 2017 Cheng (B12) 2016; 7 Ge (B25) 2017; 7 Oliva (B49) 2015; 33 Liu (B41) 2003; 47 Brockmeier (B8) 2002 Kucerova (B35) 2011; 150 Dorey (B17); 12 Odds (B47) 2003; 52 Wei (B72); 7 |
| References_xml | – year: 2015 ident: B7 publication-title: Diagnostic Solutions Critical to Limit Antimicrobial Resistance Development Confronting Antimicrobial Resistance. – volume: 6 start-page: 503 year: 2000 ident: B23 article-title: EUCAST Definitive Document E.Def 1.2, May 2000: terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. publication-title: Clin. Microbiol. Infect. doi: 10.1046/j.1469-0691.2000.00149.x – volume: 23 start-page: 329 year: 2017 ident: B53 article-title: Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens. publication-title: J. Pept. Sci. doi: 10.1002/psc.2978 – year: 2019 ident: B66 publication-title: Approved Animal Drug Products (Green Book). – volume: 33 start-page: 159 year: 1996 ident: B27 article-title: Comparison of the antigen distribution of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus. publication-title: Vet. Pathol. doi: 10.1177/030098589603300205 – year: 2002 ident: B8 article-title: Chapter 13 porcine respiratory disease complex publication-title: Polymicrobial Diseases – volume: 12 start-page: 465 year: 2014 ident: B3 article-title: Microbiological effects of sublethal levels of antibiotics. publication-title: Nat. Rev. Microbiol. doi: 10.1038/nrmicro3270 – volume: 150 start-page: 203 year: 2011 ident: B35 article-title: Antimicrobial susceptibility of Actinobacillus pleuropneumoniae isolates from clinical outbreaks of porcine respiratory diseases. publication-title: Vet. Microbiol. doi: 10.1016/j.vetmic.2011.01.016 – volume: 7 ident: B72 article-title: Florfenicol as a modulator enhancing antimicrobial activity: example using combination with thiamphenicol against Pasteurella multocida. publication-title: Front. Microbiol. doi: 10.3389/fmicb.2016.00389 – volume: 57 start-page: 2900 year: 2013 ident: B10 article-title: Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00188-13 – volume: 70 start-page: 99 year: 2008 ident: B34 article-title: Comparative pharmacokinetics of tylosin or florfenicol after a single intramuscular administration at two different doses of tylosin-florfenicol combination in pigs. publication-title: J. Vet. Med. Sci doi: 10.1292/jvms.70.99 – volume: 39 start-page: 310 year: 2019 ident: B55 article-title: Reduced resident time and tissue residues of synergistic florfenicol-thiamphenicol combination in leghorn chickens. publication-title: Pak. Vet. J. doi: 10.29261/pakveti/2019.013 – year: 1999 ident: B65 publication-title: Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. – volume: 13 year: 2018 ident: B52 article-title: Outcome of Enterococcus faecalis infective endocarditis according to the length of antibiotic therapy: preliminary data from a cohort of 78 patients. publication-title: PLoS One doi: 10.1371/journal.pone.0192387 – volume: 59 start-page: 6233 year: 2015 ident: B59 article-title: Antimicrobial peptide novicidin synergizes with rifampin, ceftriaxone, and ceftazidime against antibiotic-resistant Enterobacteriaceae In Vitro. publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01245-15 – volume: 39 start-page: 1984 year: 1995 ident: B43 article-title: Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. publication-title: Antimicro. Agents Chemother. doi: 10.1128/aac.39.9.1984 – volume: 14 year: 2018 ident: B51 article-title: Pathogenic variability among Pasteurella multocida type A isolates from Brazilian pig farms. publication-title: BMC Vet. Res. doi: 10.1186/s12917-018-1565-2 – volume: 7 year: 2017 ident: B25 article-title: Effects of low concentrations of erythromycin, penicillin, and virginiamycin on bacterial resistance development in vitro. publication-title: Sci. Rep. doi: 10.1038/s41598-017-09593-4 – volume: 18 start-page: 310 year: 2014 ident: B2 article-title: Current concepts in combination antibiotic therapy for critically ill patients. publication-title: Indian J. Crit. Care Med. doi: 10.4103/0972-5229.132495 – volume: 21 start-page: 595 year: 2012 ident: B1 article-title: In vitro susceptibility of resistant Escherichia coli field isolates to antimicrobial combinations. publication-title: Appl. Poult doi: 10.3382/japr.2011-00500 – volume: 154 start-page: 670 year: 1986 ident: B11 article-title: Correlation of antibiotic synergy in vitro and in vivo: use of an animal model of neutropenic gram negative sepsis. publication-title: J. Infect. Dis. doi: 10.1093/infdis/154.4.670 – volume: 56 start-page: 391 year: 2004 ident: B26 article-title: Comparison of checkerboard and time-kill methods for the analysis of two antibiotics combined. publication-title: Med. Dosw. Mikrobiol. – volume: 56 start-page: 917 year: 1994 ident: B30 article-title: Antibacterial activity of tilmicosin against Pasteurella multocida and Actinobacillus pleuropneumoniae isolated from pneumonic lesions in swine. publication-title: J. Vet. Med. Sci. doi: 10.1292/jvms.56.917 – volume: 25 start-page: 106 year: 2017 ident: B62 article-title: Antimicrobial susceptibility of Actinobacillus pleuropneumoniae, Pasteurella multocida, Streptococcus suis and Bordetella bronchiseptica isolated from pigs in the United States and Canada, 2011 to 2015. publication-title: J. Swine Health Prod. doi: 10.54846/jshap/1002 – volume: 57 start-page: 3990 year: 2013 ident: B63 article-title: Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00179-13 – volume: 174 year: 2014 ident: B77 article-title: Serotypes and antimicrobial resistance patterns of the recent Korean Actinobacillus pleuropneumoniae isolates. publication-title: Vet. Rec. doi: 10.1136/vr.101863 – volume: 27 start-page: 265 year: 2002 ident: B42 article-title: Tissue pharmacokinetics of florfenicol in pigs experimentally infected with Actinobacillus pleuropneumoniae. publication-title: Eur. J. Drug. Metab. Pharmacokinet. doi: 10.1007/bf03192337 – volume: 178 ident: B71 article-title: Synergism between two amphenicol of antibiotics, florfenicol and thiamphenicol, against Staphylococcus aureus. publication-title: Vet Rec. doi: 10.1136/vr.103554 – volume: 70 start-page: 1033 year: 2017 ident: B57 article-title: Suppressive drug combinations and their potential to combat antibiotic resistance. publication-title: J. Antibiot. doi: 10.1038/ja.2017.102 – volume: 16 start-page: 343 year: 1993 ident: B29 article-title: Synergy assessed by checkerboard. A critical analysis. publication-title: Diagn. Microbiol. Infect. Dis. doi: 10.1016/0732-1 – year: 2019 ident: B9 publication-title: Veterinary Drug Licenses Inquiry. – volume: 9 start-page: 212 year: 2008 ident: B61 article-title: In vitro activities of tulathromycin and ceftiofur combined with other antimicrobial agents using bovine Pasteurella multocida and Mannheimia haemolytica isolates. publication-title: Vet. Ther. – year: 2019 ident: B69 publication-title: Drug Product Database Online Query. – volume: 22 year: 2017 ident: B37 article-title: Bactericidal effect of pterostilbene alone and in combination with gentamicin against human pathogenic bacteria. publication-title: Molecules doi: 10.3390/molecules22030463 – volume: 507 start-page: 238 year: 2019 ident: B4 article-title: Combination of antimicrobials as an approach to reduce their application in aquaculture: emphasis on the use of thiamphenicol/florfenicol against Aeromonas hydrophila. publication-title: Aquaculture doi: 10.1016/j.aquaculture.2019.04.021 – year: 1999 ident: B24 publication-title: Summary Report. – volume: 26 start-page: 220 year: 1984 ident: B6 article-title: Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and –resistant Staphylococcus aureus. publication-title: Antimicrob. Agents Chemother. doi: 10.1128/aac.26.2.220 – year: 2004 ident: B45 article-title: Synergism testing: broth microdilution checkerboard and broth macrodilution methods publication-title: Clinical Microbiology Procedures Handbook – volume: 73 start-page: 37 year: 2002 ident: B19 article-title: Experimental induction of pneumonic pasteurellosis in calves by intratracheal infection with Pasteurella multocida biotype A:3. publication-title: Res. Vet. Sci. doi: 10.1016/s0034-5288(02)00037-1 – year: 2018 ident: B14 publication-title: Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals CLSI Document VET08 – volume: 10 start-page: 756 year: 2017 ident: B67 article-title: Actinobacillus pleuropneumoniae grows as aggregates in the lung of pigs: is it time to refine our in vitro biofilm assays? publication-title: Microb. Biotech. doi: 10.1111/1751-7915.12432 – volume: 7 year: 2016 ident: B12 article-title: Antimicrobial drugs in fighting against antimicrobial resistance. publication-title: Front. Microbiol. doi: 10.3389/fmicb.2016.00470 – year: 2017 ident: B58 publication-title: Design of Antimicrobial Susceptibility Testing Programmes Relevant to Aquaculture and Aquacultural Products. – volume: 47 start-page: 406 year: 2014 ident: B38 article-title: Synergy of imipenem/colistin methanesulfonate combinations against imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii. publication-title: J. Microbiol. Immunol. Infect. doi: 10.1016/j.jmii.2013.05.007 – volume: 34 start-page: S93 year: 2002 ident: B44 article-title: Antimicrobial use and resistance in animals. publication-title: Clin Infect Dis. doi: 10.1086/340246 – volume: 73 start-page: 463 year: 2011 ident: B33 article-title: Pharmacokinetics of a florfenicol-tylosin combination after intravenous and intramuscular administration to beagle dogs. publication-title: J. Vet. Med. Sci. doi: 10.1292/jvms.10-0243 – year: 2015 ident: B40 publication-title: Handbook of Pig Feeding Management and Safety Medication. – volume: 73 start-page: 205 year: 2011 ident: B75 article-title: Serotypes, antimicrobial susceptibility, and minimal inhibitory concentrations of Actionbacillus pleuropneumoniae isolated from slaughter pigs in Taiwan (2002-2007). publication-title: J. Vet. Med. Sci. doi: 10.1292/jvms.10-0339 – volume: 63 start-page: 7 year: 2017 ident: B5 article-title: Beta-lactam combination therapy for the treatment of Staphylococcus aureus and Enterococcus species bacteremia: a summary and appraisal of the evidence. publication-title: Int. J. Infect. Dis. doi: 10.1016/j.ijid.2017.07.019 – volume: 52 year: 2003 ident: B47 article-title: Synergy, antagonism, and what the chequerboard puts between them. publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkg301 – volume: 56 start-page: 909 year: 2012 ident: B28 article-title: Effects of Melaleuca alternifolia (tea tree) essential oil and the major monoterpene component terpinen-4-ol on the development of single- and multistep antibiotic resistance and antimicrobial susceptibility. publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.05741-11 – volume: 5 year: 2018 ident: B56 article-title: Incorporation of Actinobacillus pleuropneumoniae in preformed biofilms by Escherichia coli isolated from drinking water of swine farms. publication-title: Front. Vet. Sci. doi: 10.3389/fvets.2018.00184 – year: 2015 ident: B48 publication-title: OIE List of Antimicrobials of Veterinary Importance. – volume: 65 start-page: 213 year: 2001 ident: B60 article-title: Treatment of pigs experimentally infected with Mycoplasma hyopneumoniae, Pasteurella multocida, and Actinobacillus pleuropneumoniae with various antibiotics. publication-title: Can. J. Vet. Res. – volume: 115 start-page: 11495 year: 2018 ident: B68 article-title: Global trends in infectious diseases of swine. publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.1806068115 – volume: 40 start-page: 505 ident: B18 article-title: Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida. publication-title: J. Vet. Pharmacol. Ther. doi: 10.1111/jvp.12385 – volume: 40 start-page: 1914 year: 1996 ident: B73 article-title: Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. publication-title: Antimicrob. Agents Chemother. doi: 10.1128/aac.40.8.1914 – volume: 8 year: 2017 ident: B16 article-title: Synergistic effect of pleuromutilins with other antimicrobial agents against Staphylococcus aureus in vitro and in an experimental galleria mellonella model. publication-title: Front. Pharmacol doi: 10.3389/fphar.2017.00553 – volume: 50 start-page: 279 year: 2010 ident: B36 article-title: Pharmacodynamics of florfenicol alone and in combination with amoxicillin or cefuroxime against pathogenic bacteria of fish origin. publication-title: Korean J. Vet. Res. doi: 10.1111/j.1574-695X.2008.00414.x – volume: 70 start-page: 1261 year: 2008 ident: B46 article-title: Recent trends in antimicrobial susceptibility and the presence of the tetracycline resistance gene in Actinobacillus pleuropneumoniae isolates in Japan. publication-title: J. Vet. Med. Sci. doi: 10.1292/jvms.70.1261 – year: 2013 ident: B70 publication-title: Product Information Database. – volume: 8 year: 2017 ident: B74 article-title: The SapA protein is involved in resistance to antimicrobial peptide PR-39 and virulence of Actinobacillus pleuropneumoniae. publication-title: Front Microbiol. doi: 10.3389/fmicb.2017.00811 – volume: 47 start-page: 820 year: 2003 ident: B41 article-title: Pharmacokinetics of florfenicol in healthy pigs and in pigs experimentally infected with Actinobacillus pleuropneumoniae. publication-title: Antimicrob. Agents Chemother. doi: 10.1128/aac.47.2.820-823.2003 – volume: 35 start-page: 716 year: 2015 ident: B50 article-title: Pasteurella multocida type A as the primary agent of pneumonia and septicaemia in pigs. publication-title: Pesqui. Vet. Bras. doi: 10.1590/s0100-736x2015000800003 – volume: 26 start-page: 11 year: 2002 ident: B78 article-title: Comparative in vitro activity of 16 antimicrobial agents against Actinobacillus pleuropneumoniae. publication-title: Vet. Res. Commun. doi: 10.1023/A:1013397419995 – volume: 56 start-page: 353 ident: B20 article-title: In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dki204 – volume: 31 start-page: 141 year: 2011 ident: B13 article-title: The in vitro antibacterial activity of florfenicol in combination with amoxicillin or cefuroxime against pathogenic bacteria of animal origin. publication-title: Pak. Vet. J. – volume: 1 start-page: 139 year: 1988 ident: B22 article-title: Antibiotic combinations: should they be tested? publication-title: Clin. Microbiol. Rev. doi: 10.1128/cmr.1.2.139 – year: 2019 ident: B39 article-title: Serotyping and development of multilocus sequence typing (MLST) for actinobacillus pleuropneumoniae isolated from pigs in Taiwan publication-title: Proceedings of the Asain Pig Veterinary Society Congress 2019 – year: 2015 ident: B64 publication-title: Positive List System – Antibioics. – volume: 33 start-page: 132 year: 2015 ident: B49 article-title: Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen. publication-title: Int. J. Infect. Dis. doi: 10.1016/j.ijid.2015.01.011 – volume: 171 start-page: 232 year: 2014 ident: B15 article-title: Antimicrobial resistance in bacteria associated with porcine respiratory disease in Australia. publication-title: Vet. Microbiol. doi: 10.1016/j.vetmic.2014.03.014 – volume: 17 start-page: 46 ident: B21 article-title: In vitro synergy and selection of resistance by fluoroquinolones plus amikacin or beta-lactams against extended-spectrum beta-lactamase-producing Escherichia coli. publication-title: J. Chemother doi: 10.1179/joc.2005.17.1.46 – volume: 29 start-page: 153 year: 2006 ident: B31 article-title: Pharmacokinetics of florfenicol in pigs following intravenous, intramuscular or oral administration and the effects of feed intake on oral dosing. publication-title: J. Vet. Pharmacol. Ther. doi: 10.1111/j.1365-2885.2006.00727.x – volume: 181 year: 2017 ident: B76 article-title: Antimicrobial susceptibility, serotypes and genotypes of Pasteurella multocida isolates associated with swine pneumonia in Taiwan. publication-title: Vet. Rec. doi: 10.1136/vr.104023 – volume: 172 start-page: 202 year: 2014 ident: B32 article-title: Antimicrobial susceptibility monitoring of respiratory tract pathogens isolated from diseased cattle and pigs across Europe: the VetPath. study. publication-title: Vet. Microbiol. doi: 10.1016/j.vetmic.2014.04.008 – volume: 47 start-page: 2703 year: 2003 ident: B54 article-title: In vitro activities of florfenicol against bovine and porcine respiratory tract pathogens. publication-title: Antimicrob. Agents Chemother. doi: 10.1128/aac.47.8.2703-2705.2003 – volume: 12 ident: B17 article-title: Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida. publication-title: PLoS One doi: 10.1371/journal.pone.0177568 |
| SSID | ssj0000402000 |
| Score | 2.308784 |
| Snippet | Potential synergism between florfenicol (FF) and thiamphenicol (TAP) was investigated for in vitro efficacy against Actinobacillus pleuropneumoniae and/or... Potential synergism between florfenicol (FF) and thiamphenicol (TAP) was investigated for in vitro efficacy against Actinobacillus pleuropneumoniae and/or... |
| SourceID | doaj pubmedcentral proquest crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 2430 |
| SubjectTerms | Actinobacillus pleuropneumoniae florfenicol Microbiology Pasteurella multocida synergism thiamphenicol |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEBUlUOil9JNuv1Chlx7caGXZlo7b0iUttBSSQG5m9NUYXHnJ7qbk3-SnZkbehPWlvfS4XnnX9nuaeYPGT4y9L53xDmV9Mbe6LJTyVaEr4QrrnLW1rmB8K-37j_roVH07q872tvqinrDRHnh8cIfIL4eaoGpUFMqrAAJQk2gVnIYaQytFX8x5e8VUjsFUFgkxrktiFWYQps5ZauUyH8mET0zyULbrn2jMaYfkXspZPmIPd1qRL8ZrfMzuhfSE3R93j7x6yq6_Jn7ZbS4GDsnzjj5cDvz4it7my_bLfLQmXvMh8iXW5TEkwj0PPznv4Df1d-UjeDIGBiySM0588Qs6lI38-A9qUL7AkJhw2ruu77drvurJz2OVwhYZ3EHIP_cTkC3kzdwDpx5FhNzDM3a6_HLy-ajYbbhQONQlm0I1XkdZldFI66QoI4mR4FCAz0MdtbImWkx1UjqlJMwdmCjrJpoKSoc60ZfP2UEaUnjBOI5uQEgQTQBl7Rysl1ob6b2VunIwY4e3j791Ozdy2hSjb7EqIcDaDFhLgLUZsBn7cHfGanTi-MvYT4To3Tjy0M4HkFntjlntv5g1Y-9u-dDinKOFFEhh2K5bSfYBjUGWzVgzIcrkH6ffpO48u3fTwieq8pf_4xJfsQd00zmXitfsYHOxDW9QJG3s2zwfbgDZVxP1 priority: 102 providerName: Directory of Open Access Journals |
| Title | In vitro and in vivo Synergistic Effects of Florfenicol and Thiamphenicol in Combination Against Swine Actinobacillus pleuropneumoniae and Pasteurella multocida |
| URI | https://www.proquest.com/docview/2316779004 https://pubmed.ncbi.nlm.nih.gov/PMC6842999 https://doaj.org/article/880c112574f04d4ea0a92384ec8a6847 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQERIXVF5ioVRG4sIhJXGcxDkgtCCWglSE1K60t2js2G2k4Cz7KOy_4acy46SFSBUnLpHi2Hl4xjPfxPY3jL1MTVkbhPVRolUaSVlnkcpiE2ljtM5VBv2utJMv-fFcfl5kiz_bo4cOXN8Y2lE-qfmqPfr5ffcWB_wbijjR36IEGqNplVZ5RPx6GMDfRr9UUD6DkwHsB7tMoVIc93OVNzYc-aZA4T_CneNVk3-5odk-uzfgRz7tBX6f3bL-AbvTZ5TcPWS_Pnl-2WxWHQdf84ZOLjt-uqMdfoGSmfd0xWveOT7DWN1ZT7oQqp9dNPCN1nyFEmyMxgID5yA7Pj2HBqEkP_2BuJRP0Ux6NAWmadvtmi9b4vhYertFrW7Ahtt9BdQg4mtugdO6RVSDGh6x-ezD2fvjaEjCEBnEKptIFrVyIktdKbQRceoIoFiDoDyxuVNSl06j-xPCSCkgMVA6kReuzCA1iB3r9DHb8523TxjH2gXEAuLCgtQ6AV0LpUpR11qozMCEvb7q_soMDOWUKKOtMFIhgVVBYBUJrAoCm7BX1y2WPTvHP-q-I4le1yNe7VDQrc6rYZhWaM0MItCskC6WtbQQAyJghR-sIMfXn7AXV_pQ4TikyRXwttuuK0GUAkWJWjZhxUhRRk8cX_HNRWD0pslQROpP_8crPmN36aODf40P2N5mtbXPETht9GH44YDHj4vkMIyN33ZIHmo |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In+vitro+and+in+vivo+Synergistic+Effects+of+Florfenicol+and+Thiamphenicol+in+Combination+Against+Swine+Actinobacillus+pleuropneumoniae+and+Pasteurella+multocida&rft.jtitle=Frontiers+in+microbiology&rft.au=Porjai+Rattanapanadda&rft.au=Hung-Chih+Kuo&rft.au=Thomas+W.+Vickroy&rft.au=Chi-Hsuan+Sung&rft.date=2019-10-30&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-302X&rft.volume=10&rft_id=info:doi/10.3389%2Ffmicb.2019.02430&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_880c112574f04d4ea0a92384ec8a6847 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-302X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-302X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-302X&client=summon |